Insights into Chimeric Antigen Receptor Therapy for Chronic Lymphoblastic Leukemia
- PMID: 30149852
- DOI: 10.1016/j.molmed.2018.06.007
Insights into Chimeric Antigen Receptor Therapy for Chronic Lymphoblastic Leukemia
Abstract
In a recent study, Fraietta and colleagues identified chimeric antigen receptor (CAR) T cell biomarkers that may predict the success or failure of CAR therapy in patients with refractory chronic lymphoblastic leukemia (CLL). These findings open new prospects for improving T cell product manufacturing and the management of patients with CLL undergoing T cell-based therapies.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Comment on
-
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.Nat Med. 2018 May;24(5):563-571. doi: 10.1038/s41591-018-0010-1. Epub 2018 Apr 30. Nat Med. 2018. PMID: 29713085 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources